Nerea Vega García
Jefe de Grupo
Research group
After obtaining her Degree in Human Biology (Pompeu Fabra University) in 2012, Nerea Vega improve her skills in clinical laboratory techniques at the Master Laboratory of Clinical Analysis (Pompeu Fabra University) in 2013.
After starting her doctoral research at the Laboratory of Hematology of the SJD Barcelona Children’s Hospital, included in the Group of Tumors of the Development of the Institut de Recerca Sant Joan de Déu. In 2018 s he obtained her PhD in Medicine and Translational Research (Universitat of Barcelona).
Her research, entitled "Study of the histone deacetylase (HDAC) expression profile in paediatric patients with acute leukaemia" focused on the study of the expression profile of HDAC and other corregulators in order to improve our knowledge on their role in paediatric leukaemia and identify possible biomarkers and/or therapeutic targets, especially in high-risk leukemias such as infants and MLL-rearranged.
Currently, and thanks to the experience obtained during these 7 years in the Hematology Laboratory in molecular techniques, and after attending several formations (national and international) She has participated in the implementation of NGS techniques for the molecular diagnosis of patients with paediatric acute leukaemia. Moreover, she participates in national and international scientific congresses and associations, including the European Hematology Association (EHA).
Professional network profiles
Last Publications
- Bueno C, Torres-Ruíz R, Velasco-Hernandez T, Molina O, Petazzi P, Martinez-Moreno A, Rodríguez-Cortez VC, Vinyoles M, Cantilena S, Williams O, Vega-García N, Rodriguez-Perales S, Segovia JC, Quintana-Bustamante O, Roy A, Meyer C, Marschalek R, Smith A, Milne TA, Fraga MF, Tejedor JRR and Menendez P A human genome editing-based MLL::AF4 ALL model recapitulates key cellular and molecular leukemogenic features Blood . 142(20): 1752-1756.
- Velasco P, Bautista F, Rubio A, Aguilar Y, Rives-Solà S, Dapena JL, Pérez A, Ramirez M, Saiz-Ladera C, Izquierdo E, Escudero A, Camós-Guijosa M, Vega-García N, Ortega M, Hidalgo-Gómez G, Palacio C, Menéndez P, Bueno C, Montero J, Romecín PA, Zazo S, Alvarez F, Parras J, Ortega-Sabater C, Chulián S, Rosa M, Cirillo D, García E, García J, Manzano-Muñoz A, Minguela A and Fuster JL The relapsed acute lymphoblastic leukemia network (ReALLNet): a multidisciplinary project from the spanish society of pediatric hematology and oncology (SEHOP) Frontiers in pediatrics . 11: 1269560-1269560.
- Esperanza-Cebollada E, Gomez-Gonzalez S, Pérez-Jaume S, Vega-García N, Vicente-Garces C, Richarte M, Rives-Solà S, Català-Temprano A, Torrebadell-Burriel M and Camós-Guijosa M A miRNA signature related to stemness identifies high-risk patients in paediatric acute myeloid leukaemia BRITISH JOURNAL OF HAEMATOLOGY . 202(1): 96-110.
Projects
- Project name:
- Nuevas técnicas para la caracterización molecular completa y la mejora del seguimiento de la enfermedad mínima residual en leucemia aguda pediátrica
- Leader
- Mireia Camós Guijosa, Nerea Vega García
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI21/00213
- Starting - finishing date:
- 2022 - 2025
- Project name:
- SGR 2022-2024_Grup de recerca en tumors del desenvolupament
- Leader
- Jaume Mora Graupera
- Funding entities:
- Agaur - Agència de Gestió d'Ajuts Universitaris i de Recerca
- Code
- 2021 SGR 01612
- Starting - finishing date:
- 2022 - 2025
- Project name:
- CLOSER: Childhood Leukemia: Overcoming distance between South America and Europe Regions
- Leader
- Mireia Camós Guijosa
- Funding entities:
- European Commission
- Code
- 825749
- Starting - finishing date:
- 2019 - 2024
News
-
The hidden cells behind B-cell acute lymphoblastic leukemia relapse spotlighted for the first time
Drs. Susana Rives, Montserrat Torrebadell and Nerea Vega (IRSJD) participate in a study led by Dr. Pablo Menéndez, group leader at the Josep Carreras Leukaemia Research Institut, who has identified a previously noticed population of pre-leukemic cells might be responsible for some relapses in B-cell acute lymphoblastic leukemia (B-ALL).